SCHEMBL4526407

SCHEMBL4526407

COc1cccc(Cn2c(=O)n(-c3cccc(OC)c3)c3nc(N4CCCC4)ncc32)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 8/20 0.60
ADORA1 P30542 8/20 0.60
ALDH1A1 P00352 12/20 0.58
CYP3A4 P08684 10/20 0.58
USP2 O75604 10/20 0.58
CYP1A2 P05177 8/20 0.58
CYP2D6 P10635 6/20 0.58
CYP2C9 P11712 6/20 0.58
HSD17B10 Q99714 3/20 0.58
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
CLK4 Q9HAZ1 1/20 0.58
CYP2C19 P33261 7/20 0.57
TSHR P16473 3/20 0.57
MAPK1 P28482 2/20 0.57
HPGD P15428 1/20 0.57
HIF1A Q16665 7/20 0.54
CASP1 P29466 6/20 0.52
CASP7 P55210 6/20 0.52
GLA P06280 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13966202 0.81 ADORA2A (0.68) ADORA2AADORA1
SCHEMBL4515959 0.81 CYP1A2 (0.66) ADORA2AADORA1ALDH1A1CYP3A4USP2
SCHEMBL4531259 0.80 ADORA2A (0.91) ADORA2AADORA1
SCHEMBL4520036 0.79 ADORA2A (0.72) ADORA2AADORA1ALDH1A1CYP3A4USP2
SCHEMBL13966250 0.76 ADORA2A (0.92) ADORA2AADORA1
SCHEMBL13966151 0.76 ADORA2A (0.84) ADORA2AADORA1
SCHEMBL13966138 0.76 ADORA2A (0.84) ADORA2AADORA1
SCHEMBL13966174 0.76 ADORA2A (0.83) ADORA2AADORA1
SCHEMBL13966216 0.76 ADORA2A (0.63) ADORA2AADORA1
SCHEMBL13966218 0.76 ADORA2A (0.83) ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023723-A1 Purinone derivatives for treating neurodegenerative diseases PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2009-01-22 US disclosed
US-20090023723-A1 Purinone derivatives for treating neurodegenerative diseases PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2009-01-22 US disclosed
US-20090023723-A1 Purinone derivatives for treating neurodegenerative diseases PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2009-01-22 US disclosed
WO-2007035873-A1 PURINONE DERIVATIVES FOR TREATING NEURODEGENERATIVE DISEASES PHARMACOPEIA, INC. (US) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023723-A1 Purinone derivatives for treating neurodegenerative diseases ADORA2A, P2RX6, P2RX5 ADORA2A 1/4885ADORA1 9/4885ALDH1A1 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.